Evidence map›Paper›PMID 22961545›Full record

ArticleBrain : a journal of neurology2012

Lysosomal dysfunction causes neurodegeneration in mucolipidosis II 'knock-in' mice.

K Kollmann, M Damme, S Markmann, W Morelle, M Schweizer, I Hermans-Borgmeyer, A K Röchert, S Pohl, T Lübke, J-C Michalski and 3 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Novel Phenotypical and Biochemical Findings in Mucolipidosis Type II.International journal of molecular sciences · 2025
    Article
  6. Article
  7. α-Synuclein: Multiple pathogenic roles in trafficking and proteostasis pathways in Parkinson's disease.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Glycan degradation promotes macroautophagy.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Mucolipidoses Overview: Past, Present, and Future.International journal of molecular sciences · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

K KollmannDepartment of Biochemistry, Children’s Hospital, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
M Damme
S Markmann
W Morelle
M Schweizer
I Hermans-Borgmeyer
A K Röchert
S Pohl
T Lübke
J-C Michalski
R Käkelä
S U Walkley
T Braulke

Funding

Endosomal-Lysosomal Function in Neuronal Storage DiseaseR01HD045561 · NICHD · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI DOBRENIS, KOSTANTIN, WALKLEY, STEVEN UPSHAW · 2004 to 2021
$6.9M
Translational Neuroimaging CoreP30HD071593 · NICHD · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI WALKLEY, STEVEN UPSHAW · 2011 to 2015
$5.6M
NICHD NIH HHS P30 HD071593NICHD NIH HHS R01 HD045561
6 · The paper itself

Abstract

Mucolipidosis II is a neurometabolic lysosomal trafficking disorder of infancy caused by loss of mannose 6-phosphate targeting signals on lysosomal proteins, leading to lysosomal dysfunction and accumulation of non-degraded material. However, the identity of storage material and mechanisms of neurodegeneration in mucolipidosis II are unknown. We have generated 'knock-in' mice with a common mucolipidosis II patient mutation that show growth retardation, progressive brain atrophy, skeletal abnormalities, elevated lysosomal enzyme activities in serum, lysosomal storage in fibroblasts and brain and premature death, closely mimicking the mucolipidosis II disease in humans. The examination of affected mouse brains at different ages by immunohistochemistry, ultrastructural analysis, immunoblotting and mass spectrometric analyses of glycans and anionic lipids revealed that the expression and proteolytic processing of distinct lysosomal proteins such as α-l-fucosidase, β-hexosaminidase, α-mannosidase or Niemann-Pick C2 protein are more significantly impacted by the loss of mannose 6-phosphate residues than enzymes reaching lysosomes independently of this targeting mechanism. As a consequence, fucosylated N-glycans, GM2 and GM3 gangliosides, cholesterol and bis(monoacylglycero)phosphate accumulate progressively in the brain of mucolipidosis II mice. Prominent astrogliosis and the accumulation of organelles and storage material in focally swollen axons were observed in the cerebellum and were accompanied by a loss of Purkinje cells. Moreover, an increased neuronal level of the microtubule-associated protein 1 light chain 3 and the formation of p62-positive neuronal aggregates indicate an impairment of constitutive autophagy in the mucolipidosis II brain. Our findings demonstrate the essential role of mannose 6-phosphate for selected lysosomal proteins to maintain the capability for degradation of sequestered components in lysosomes and autophagolysosomes and prevent neurodegeneration. These lysosomal proteins might be a potential target for a valid therapeutic approach for mucolipidosis II disease.

Indexed as

alpha-L-Fucosidasealpha-MannosidaseAnimalsAtrophyAutophagybeta-N-AcetylhexosaminidasesBrainDisease Models, AnimalLysosomesMiceMice, TransgenicMucolipidosesNerve DegenerationVesicular Transport Proteinsalpha-L-Fucosidasealpha-Mannosidasebeta-N-AcetylhexosaminidasesNpc2 protein, mouseVesicular Transport Proteins

Identifiers

PMID22961545
PMCPMC3437033

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.